Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

13. oktober 2010 oppdatert av: GlaxoSmithKline

A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.

Data suggests that imaging activity of the brain can measure the effects of anti-anxiety drugs. This study will investigate the effect of GW876008 on areas of the brain involved with thinking and emotion

Studieoversikt

Status

Fullført

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

26

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • La Jolla, California, Forente stater, 92093
        • GSK Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 50 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Healthy males or females aged 18-50 years, inclusive.
  • STAI-trait score = or > 40.
  • STAI-state score <50th percentile of the normal population distribution.
  • Female subjects of non-childbearing.
  • Female subjects of childbearing potential must agree to use appropriate contraception.
  • Healthy subjects, as determined by a responsible physician
  • Body weight ≥ 50 kg (110 lbs), and BMI within the range 19-29.9 kg/m2 inclusive.
  • Demonstrates no significant evidence of active disease, physical or mental impairment when assessed by qualified personnel
  • Non-smoker (abstinence from smoking for at least 6 months before the start of the study).
  • Normal electrocardiogram.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Read, comprehend, and write English at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation

Exclusion Criteria:

  • As a result of any of the medical interview, physical examination, evaluation of mental state and psychiatric history or screening investigations the physician responsible considers the subject unfit for the study.
  • Any history of suicidal attempts or behaviour.
  • Any history or current diagnosis of a psychiatric illness.
  • Any history of an endocrine disorder including, but not limited to, diabetes or disorders of the hypothalamus, pituitary, adrenal, or thyroid glands, or gonadal disorder or dysfunction of the reproductive organs.
  • Abnormal pepsinogen I level at screening.
  • Liver Function Tests (LFTs) elevated above the reference range at pre-study screening that remain elevated with a repeat LFT
  • Any other clinically significant laboratory abnormality.
  • Positive faecal occult blood test.
  • Positive pre-study urine drug/alcohol breath screen.
  • Positive pre-study HIV 1/2, Hepatitis B surface antigen and positive Hepatitis C antibody result within 3 months of the start of the study.
  • Pre-existing or current Helicobactor pylori infection.
  • History of alcohol/drug abuse or dependence within 12 months of the study
  • Consumption of grapefruit juice or grapefruit within 14 days prior to the first dose of study medication.
  • History of peptic ulcer disease.
  • Abnormal screening ECG
  • History of long QT syndrome (personal or family) or other cardiac conduction disorder, or other clinically significant cardiac disease.
  • Systolic blood pressure < 90mmHg or >140mmHg; diastolic blood pressure < 60mmHg or > 90mmHg; pulse rate < 40bpm or > 90bpm.
  • Participation in a clinical trial with a drug or new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History or current diagnosis of acute narrow angle glaucoma.
  • Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period.
  • Current or recent (within one year) gastrointestinal disease; a history of malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a week) occurrence of heartburn; or any surgical intervention (e.g., cholecystectomy) which would be expected to influence the absorption of drugs.
  • Average daily caffeine intake equivalent to > 4 cups of coffee or > 6 cups of tea.
  • Subjects who are left handed.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Hva måler studien?

Primære resultatmål

Resultatmål
Differences in brain activation elicited by Matching Emotional Face Expression paradigm following single oral doses of GW876008 and lorazepam on day 1, sessions 1-4

Sekundære resultatmål

Resultatmål
Tidsramme
Kliniske laboratorietester
GW876008 blood levels
Tidsramme: pre-dose & post-dose, sessions 1-4
pre-dose & post-dose, sessions 1-4
clinical rating scales change after dosing: questionnaires collected
Tidsramme: pre-dose & up to 6-8 hours post-dose.
pre-dose & up to 6-8 hours post-dose.
Safety: 12-lead ECG, vital signs, adverse events, clinical labs
fMRI BOLD neuroanatomical structure of the emotional brain neurocircuitry and connectivity
fMRI BOLD Signal characteristics and connectivity
fMRI BOLD Response in the emotional brain neurocircuitry and occipital cortex.
ETCo2 in mm Hg, to be recorded for the duration of the scan session and be synchronized with the single fMRI procedure timing
Visual Analog Scale (VAS) measurements of sleepiness, alertness, calm, tension, and anxiety performed before dosing (baseline), pre-fMRI session, post-fMRI session and just before leaving the facility.
Association between the anxiety trait (STAI-trait, test battery for neuroticism or liability for Anxiety Disorders) collected at screening and the various pharmacodynamic parameters measured in the various testing conditions.
GW876008 concentration to determine pharmacokinetic parameters to be collected twice per session,
Pharmacogenetic (PGx) assessments
Safety and tolerability of GW876008 to include Vital signs semi-supine; respiratory rate, pulse oximetry and ECG.
fMRI BOLD ALS signal.
Heart rate (HR; beats per minute), to be recorded for the whole duration of the scan session and to be synchronized with the single fMRI procedure timing.
Respiratory rate (RR: inspiration per minute), to be recorded for the duration of scan session and be synchronized with the single fMRI procedure timing. .

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: GSK Clinical Trials, MBChB, MFPM, GlaxoSmithKline

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. mars 2007

Primær fullføring (Faktiske)

1. desember 2007

Studiet fullført (Faktiske)

1. desember 2007

Datoer for studieregistrering

Først innsendt

17. januar 2007

Først innsendt som oppfylte QC-kriteriene

18. januar 2007

Først lagt ut (Anslag)

19. januar 2007

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

15. oktober 2010

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. oktober 2010

Sist bekreftet

1. oktober 2010

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere